ENvue Medical, Inc.
$1.51
▼
-5.31%
2026-04-21 06:49:00
envuemed.com
NCM: FEED
Explore ENvue Medical, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$5.59 M
Current Price
$1.51
52W High / Low
$75.48 / $0.99
Stock P/E
—
Book Value
$42
Dividend Yield
—
ROCE
-394.93%
ROE
-30.51%
Face Value
—
EPS
$-51.81
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
31
Beta
2.1
Debt / Equity
7.46
Current Ratio
0.86
Quick Ratio
0.42
Forward P/E
—
Price / Sales
0.67
Enterprise Value
$-1.97 M
EV / EBITDA
0.22
EV / Revenue
-0.73
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | TransMedics Group, Inc. | $113.13 | 20.39 | $3.88 B | — | 11.09% | 54.24% | $156 / $84.53 | $13.81 |
| 2. | Insulet Corporation | $193.4 | 55.6 | $13.48 B | — | 18.87% | 18.12% | $354.88 / $194.61 | $21.53 |
| 3. | Baird Medical Investment Holdings Limited | $1.79 | 55.75 | $64.64 M | — | 35.34% | -8.03% | $7.26 / $0.76 | $1.34 |
| 4. | Nexalin Technology, Inc. | $0.47 | — | $9.54 M | — | -223.88% | -2.22% | $2 / $0.33 | $0.2 |
| 5. | Cytosorbents Corporation | $0.65 | — | $41.24 M | — | -41.3% | -96.39% | $1.39 / $0.5 | $0.09 |
| 6. | TELA Bio, Inc. | $0.63 | — | $30.55 M | — | -53.21% | -2.23% | $2.2 / $0.5 | $0.14 |
| 7. | SS Innovations International, Inc. | $4.85 | — | $971.12 M | — | -17.08% | -46.94% | $22.42 / $3.02 | $0.2 |
Quarterly Results
Figures shown in M / B
| Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|
| Sales | 0.72 M | 0.49 M | 1.02 M | 0.44 M | 0.38 M |
| Operating Profit | -2.25 M | -3.98 M | -1.85 M | -1.37 M | -0.97 M |
| Net Profit | 0.51 M | -3.97 M | -2.5 M | -1.43 M | -1 M |
| EPS in Rs | 0.47 | -3.65 | -2.29 | -1.32 | -0.92 |
Profit & Loss
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Sales | 2.56 M | 2.28 M | 0.75 M | 1.7 M |
| Operating Profit | -3.58 M | -3.44 M | -5.01 M | -5.68 M |
| Net Profit | -3.71 M | -3.71 M | -5.45 M | -14.28 M |
| EPS in Rs | -3.4 | -3.41 | -5.01 | -13.12 |
Balance Sheet
Figures shown in M / B
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Total Assets | 3.63 M | 6.67 M | 5.88 M | 8.62 M |
| Total Liabilities | 3 M | 2.69 M | 2.65 M | 2.31 M |
| Equity | 0.63 M | 3.99 M | 3.23 M | 6.31 M |
| Current Assets | 3.33 M | 6.49 M | 5.61 M | 8.34 M |
| Current Liabilities | 2.72 M | 2.45 M | 2.32 M | 1.9 M |
Cash Flow
Last available yearly cash flow history
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Operating CF | -2.52 M | -3.6 M | -7.04 M | -4.37 M |
| Investing CF | -0 M | -0 M | -0 M | -0 M |
| Financing CF | 0 M | 4.22 M | 2.09 M | 4.58 M |
| Free CF | -2.52 M | -3.6 M | -7.04 M | -4.37 M |
| Capex | -0 M | -0 M | -0 M | -0 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 12.05% | 203.59% | -55.63% | — |
| Earnings Growth % | 0.16% | 31.88% | 61.85% | — |
| Profit Margin % | -144.84% | -162.55% | -724.47% | -842.6% |
| Operating Margin % | -140.03% | -150.5% | -666.49% | -335.28% |
| Gross Margin % | 58.95% | 67.32% | 22.21% | 45.43% |
| EBITDA Margin % | -138.78% | -155.32% | -673.54% | -840.59% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-08-12 | 1:0.1 |
| 2025-03-14 | 1:0.0909091 |
| 2023-02-09 | 1:0.05 |